Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 Clinical Trials
2 recruitingBiologic
Phase 12Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Non-Malignant Neoplasm
Fred Hutchinson Cancer Center40 enrolled1 locationNCT04083183
Recruiting
Phase 1Phase 2
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966